SEVERE ACUTE RESPIRATORY SYNDROME (SARS) TREATMENT MARKET ANALYSIS

Severe Acute Respiratory Syndrome (SARS) Treatment MarketSize and Trends

Global Severe Acute Respiratory Syndrome (SARS) Treatment Market – Dynamics

Rising cases of COVID-19 is expected to propel growth of the SARS treatment market across globe over the forecast period. As stated by the World Health Organization, over 170.8 million confirmed cases and 3.5 million deaths of coronavirus disease (COVID-19) were reported up till June 2, 2021 across the globe.

Increasing drug approvals for emergency use authorization (by regulatory authorities) for the treatment of COVID-19 has led to a dynamic surge in SARS treatment market. For instance, the Drug Controller General of India approved the drug known as 2-DG, which is a powdered form of the molecule 2-deoxy-D-glucose developed by the Institute of Nuclear Medicine and Allied Sciences (INMA), a leading laboratory of the Defense Research and Development Organization (DRDO) in collaboration with Dr. Reddy’s laboratories (DRL), for emergency use in May 2021. The results of the clinical trials demonstrated that 2-DG helps the moderate and severe COVID-19 patients to recover faster and also decreases the need of supplemental oxygen. Moreover, US Food drug and administration (FDA) approved GlaxoSmithKline developed medication known as Sotrovimab, for emergency use on June 1, 2021. Sotrovimab is a monoclonal antibody which would be used for treating mild to moderate COVID-19 patients.

In addition, scientists are still researching and experimenting for a valid cure against COVID-19, which leaves a scope for more new launches in future, thereby leading to a boost in the SARS treatment market. For instance, according to the U.S. Food and drugs administration (FDA) Coronavirus Treatment Acceleration Program (CTAP) dashboard, as of April 2021, more than 610 drug development programs are in planning stages and above 450 trials are being reviewed for the treatment of COVID-19.